


Government of Pakistan
Drug Regulatory Authority of Pakistan
Ministry of National Health Services, Regulations and Coordination

Islamabad, the 12th October, 2022

NOTIFICATION

S.R.O. 1888 (I)/2022. – In exercise of the powers conferred by sub-rule (1) of rule 13 of the Bio-Study Rules, 2017, the Drug Regulatory Authority of Pakistan, with the approval of the Federal Government, is pleased to notify the Clinical Studies Committee, for a period of three years, namely:–

Sr.	Name & Designation	Position
1.	Director , Division of Pharmacy Services, Drug Regulatory Authority of Pakistan, in terms of clause (a) of sub-rule (1) of rule 13 of the said rules.	<i>Ex-officio</i> Chairman
2.	Additional Director or Deputy Director , Pharmacy Services Division, Drug Regulatory Authority of Pakistan, in terms of clause (b) of sub-rule (1) of rule 13 of the said rules.	<i>Ex-officio</i> Secretary
3.	Chairman, Pakistan Health Research Council or his/her nominee, in terms of clause (c) of sub-rule (1) of rule 13 of the said rules.	<i>Ex-officio</i> Member
4.	Dr. Mirza Tasawer Baig , Associate Professor in the Department of Pharmacy Practice, Faculty of Pharmacy, Ziauddin University, Karachi & Clinical Pharmacist at Dr. Ziauddin Hospital, Karachi. (Sindh) , in terms of clause (d) of sub-rule (1) of rule 13 of the said rules.	Member
5.	Prof. Munawar Alam Ansari , Professor of Pharmacology, Dean Faculty of Pharmacy, Liaquat University of Medical Sciences, Jamshoro. (Sindh) , in terms of clause (e) of sub-rule (1) of rule 13 of the said rules.	Member
6.	Prof. Dr. Fazel e Subhan , Department of Pharmacy, CECOS University of IT & Emerging Sciences, Hayatabad, Peshawar, (Khyber Pakhtunkhwa) , in terms of clause (f) of sub-rule (1) of rule 13 of the said rules.	Member
7.	Prof. Dr. Saeed Ahmad Khan , Professor of Medicine Bolan Medical College Quetta presently serving as head of medicine department Jhalawan Medical College, Khuzdar. (Balochistan) , in terms of clause (g) of sub-rule (1) of rule 13 of the said rules.	Member
8.	Mr. Waqas Latif , Data Analyst/Biostatistician in Quality Enhancement Cell (QEC) at University of Health Sciences, Lahore. (Punjab) , in terms of clause (h) of sub-rule (1) of rule 13 of the said rules.	Member
9.	One representative to be nominated by Pakistan Pharmaceutical Manufacturers Association having fifteen years of experience and expertise of conducting Clinical Trials and BA or BE studies in terms of clause (i) of sub-rule (1) of rule 13 of the said rules.	Observer
10.	One representative to be nominated by the Pharma Bureau having fifteen years of experience and expertise of Clinical Trials and BA or	Observer



	BE studies in terms of clause (i) of sub-rule (1) rule 13 of the said rules.	
--	--	--

2. The Committee may co-opt member to be nominated by the Committee for therapeutic goods or any other specific matter in terms of clause (j) of sub-rule (1) of rule 13 of the said rules.

[No. F.13-1/2017-DD(PS)]



HAFIZ BILAL BIN AKBAR
Deputy Director (Legal Affairs)